Song Taejong, Lee Doo Haeng, Jung Yong Wook, Yun Bo Seong, Seong Seok Ju, Choi Chel Hun, Lee Jeong-Won, Bae Duk-Soo, Kim Byoung-Gie
Department of Obstetrics and Gynecology, Kangbuk Samsung Hospital, Seoul, Korea.
Gynecol Obstet Invest. 2018;83(1):45-51. doi: 10.1159/000475817. Epub 2017 Jun 2.
To investigate whether elevated levels of CA125 (≥35 U/mL) and CA19-9 (≥37 U/mL) suggest advanced-stage disease (defined as stage II or higher) or poor prognosis in patients with borderline ovarian tumors (BOTs).
We retrospectively identified 591 patients with BOTs. Multivariate logistic regressions and Cox proportional hazard regressions were used to determine the clinicopathologic factors associated with the presence of advanced-stage disease and the prognostic factors associated with recurrence-free survival.
CA125 was elevated more often in serous than in mucinous tumors (50.6 vs. 35.5%; p = 0.003), whereas CA19-9 was elevated more often in mucinous than serous tumors (33.6 vs. 15.3%; p = 0.001). An elevated CA125 level was independently associated with the presence of advanced-stage disease in serous (p = 0.005) and in mucinous BOTs (p = 0.015). However, preoperative elevation of CA19-9, unlike CA125, was not associated with the advanced-stage disease. Elevated preoperative CA125 level (p = 0.037) was an independent prognostic factor for recurrence-free survival in patients with serous BOTs. However, neither CA125 nor CA19-9 had prognostic significance in mucinous BOTs.
Elevated preoperative CA125, unlike CA19-9, is a diagnostic and prognostic biomarker associated with the presence of advanced-stage disease and risk of relapse in patients with serous BOTs.
探讨CA125水平升高（≥35 U/mL）和CA19-9水平升高（≥37 U/mL）是否提示卵巢交界性肿瘤（BOTs）患者存在晚期疾病（定义为II期或更高分期）或预后不良。
我们回顾性纳入了591例BOTs患者。采用多因素logistic回归和Cox比例风险回归分析来确定与晚期疾病存在相关的临床病理因素以及与无复发生存相关的预后因素。
浆液性肿瘤中CA125升高的情况比黏液性肿瘤更常见（50.6%对35.5%；p = 0.003），而黏液性肿瘤中CA19-9升高的情况比浆液性肿瘤更常见（33.6%对15.3%；p = 0.001）。CA125水平升高与浆液性（p = 0.005）和黏液性BOTs（p = 0.015）患者的晚期疾病存在独立相关。然而，与CA125不同，术前CA19-9升高与晚期疾病无关。术前CA125水平升高（p = 0.037）是浆液性BOTs患者无复发生存的独立预后因素。然而，CA125和CA19-9在黏液性BOTs中均无预后意义。
与CA19-9不同，术前CA125升高是与浆液性BOTs患者晚期疾病存在和复发风险相关的诊断和预后生物标志物。
